Antigens, Neoplasm

Publication Title: 
Scientific Reports

The physiological roles of the protease inhibitor SERPINB3 (SB3) are still largely unknown. The study was addressed to assess the biological effects of this serpin in vivo using a SB3 transgenic mouse model. Two colonies of mice (123 transgenic for SB3 and 148 C57BL/6J controls) have been studied. Transgenic (TG) mice showed longer survival than controls and the difference was more remarkable in males than in females (18.5% vs 12.7% life span increase). In TG mice decreased IL-6 in serum and lower p66shc in the liver were observed.

Villano, Gianmarco
Ruvoletto, Mariagrazia
Ceolotto, Giulio
Quarta, Santina
Calabrese, Fiorella
Turato, Cristian
Tono, Natascia
Biasiolo, Alessandra
Cattelan, Arianna
Merkel, Carlo
Avogaro, Angelo
Gatta, Angelo
Pontisso, Patrizia
Publication Title: 

AIM: We investigated methylation of DNA repetitive sequences (LINE-1 and BAGE) in peripheral blood leukocytes from first-episode schizophrenia (FES) patients and healthy controls (HCs) with respect to childhood adversities. MATERIALS & METHODS: Patients were divided into two subgroups based on the history of childhood trauma - FES(+) and FES(-) subjects. The majority of HCs had a negative history of childhood trauma - HCs(-) subjects. RESULTS: FES(+) patients had significantly lower LINE-1 methylation in comparison with FES(-) patients or HC(-) subjects.

Misiak, B?a?ej
Szmida, El?bieta
Karpi?ski, Pawe?
Loska, Olga
S?siadek, Maria M.
Frydecka, Dorota
Publication Title: 
Anticancer Research

Classical therapeutic modalities such as surgery, radiation and chemotherapy not only fail to cure the majority of neoplastic disease, but their employment also leads to severe and debilitating side effects. The severe cancer related morbidity is often associated with the use of radiation and chemotherapy, making them less than ideal forms of therapy.

Bodey, B.
Siegel, S. E.
Kaiser, H. E.
Publication Title: 
Expert Opinion on Biological Therapy

Classical antineoplastic therapeutic modalities such as surgery, radiation, and chemotherapy not only fail to cure the great majority of neoplasms, but their employment often leads to severe and debilitating side effects associated with severe neoplasm-related morbidity. Immunotherapy as a fourth modality of anti-cancer therapy has already been proven to be quite effective.

Bodey, B.
Publication Title: 
Cancer Immunity

A differentiation antigen commonly expressed on melanoma cells, gp100 is the target of infiltrating T cells. We conducted a phase I randomized cross-over trial of melanoma patients with either xenogeneic (mouse) or human gp100 plasmid DNA injected intramuscularly at three dosages (100, 500 or 1,500 microg) every three weeks for three doses. After the first three injections, patients were then immunized three times with gp100 from the other species.

Yuan, Jianda
Ku, Geoffrey Y.
Gallardo, Humilidad F.
Orlandi, Francesca
Manukian, Gregor
Rasalan, Teresa S.
Xu, Yinyan
Li, Hao
Vyas, Shachi
Mu, Zhenyu
Chapman, Paul B.
Krown, Susan E.
Panageas, Katherine
Terzulli, Stephanie L.
Old, Lloyd J.
Houghton, Alan N.
Wolchok, Jedd D.
Publication Title: 
Thrombosis and Haemostasis

High-mobility group box 1 protein (HMGB1), an abundant nuclear protein, was recently established as a proinflammatory mediator of experimental sepsis. Although extracellular HMGB1 has been found in atherosclerotic plaques, its potential role in the pathogenesis of atherothrombosis remains elusive. In the present study, we determined whether HMGB1 induces tissue factor (TF) expression in vascular endothelial cells (ECs) and macrophages. Our data showed that HMGB1 stimulated ECs to express TF (but not TF pathway inhibitor) mRNA and protein in a concentration- and time-dependent manner.

Lv, Ben
Wang, Haichao
Tang, Yiting
Fan, Zhang
Xiao, Xianzhong
Chen, Fangping
Publication Title: 
Cancer immunology, immunotherapy: CII

BACKGROUND: Anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies, such as ipilimumab, have generated measurable immune responses to Melan-A, NY-ESO-1, and gp100 antigens in metastatic melanoma. Vaccination against such targets has potential for immunogenicity and may produce an effector-memory T-cell response.

Yuan, Jianda
Ginsberg, Brian
Page, David
Li, Yanyun
Rasalan, Teresa
Gallardo, Humilidad F.
Xu, Yinyan
Adams, Sylvia
Bhardwaj, Nina
Busam, Klaus
Old, Lloyd J.
Allison, James P.
Jungbluth, Achim
Wolchok, Jedd D.
Publication Title: 
The New England Journal of Medicine

To compare the clinical usefulness of the serum markers prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP), we measured them by radioimmunoassay in 2200 serum samples from 699 patients, 378 of whom had prostatic cancer. PSA was elevated in 122 of 127 patients with newly diagnosed, untreated prostatic cancer, including 7 of 12 patients with unsuspected early disease and all of 115 with more advanced disease. The PSA level increased with advancing clinical stage and was proportional to the estimated volume of the tumor.

Stamey, T. A.
Yang, N.
Hay, A. R.
McNeal, J. E.
Freiha, F. S.
Redwine, E.
Publication Title: 
Human Gene Therapy

Thirty-three metastatic melanoma patients were vaccinated according to a phase I-II study with an allogeneic melanoma cell line that was genetically modified by transfection with a plasmid containing the gene encoding human interleukin 2 (IL-2). The cell line expresses the major melanoma-associated antigens and the HLA class I alleles HLA-A1, -A2, -B8, and Cw7. All patients shared one or more HLA class I alleles with this cell line vaccine.

Osanto, S.
Schiphorst, P. P.
Weijl, N. I.
Dijkstra, N.
Van Wees, A.
Brouwenstein, N.
Vaessen, N.
Van Krieken, J. H.
Hermans, J.
Cleton, F. J.
Schrier, P. I.
Publication Title: 
Current Opinion in Immunology

Following vaccination with defined tumor antigens that are recognized by T cells, a small proportion of cancer patients display tumor regressions. Several reports describe anti-vaccine T-cell responses, evaluated with a variety of methods, for example, by assessing T-cell function or expression of specific TCR. However, a correlation between these T-cell responses and the tumor regressions has not yet been established. It appears that some patients display tumor regression with an unexpectedly low frequency of anti-vaccine T cells.

Coulie, Pierre G.
van der Bruggen, Pierre


Subscribe to RSS - Antigens, Neoplasm